S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
California authorizes expansion of Waymo's driverless car services to LA, SF peninsula
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
College athletes will need school approval for NIL deals under bill passed by Utah Legislature
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
California authorizes expansion of Waymo's driverless car services to LA, SF peninsula
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
College athletes will need school approval for NIL deals under bill passed by Utah Legislature
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
California authorizes expansion of Waymo's driverless car services to LA, SF peninsula
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
College athletes will need school approval for NIL deals under bill passed by Utah Legislature
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
California authorizes expansion of Waymo's driverless car services to LA, SF peninsula
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
College athletes will need school approval for NIL deals under bill passed by Utah Legislature

Esperion Therapeutics (ESPR) Competitors

$2.55
+0.04 (+1.59%)
(As of 03/1/2024 ET)

ESPR vs. VSTM, ATAI, AKBA, QURE, HOWL, ACIU, ME, SBTX, NATR, and NBTX

Should you be buying Esperion Therapeutics stock or one of its competitors? The main competitors of Esperion Therapeutics include Verastem (VSTM), Atai Life Sciences (ATAI), Akebia Therapeutics (AKBA), uniQure (QURE), Werewolf Therapeutics (HOWL), AC Immune (ACIU), 23andMe (ME), Silverback Therapeutics (SBTX), Nature's Sunshine Products (NATR), and Nanobiotix (NBTX). These companies are all part of the "pharmaceutical preparations" industry.

Esperion Therapeutics vs.

Verastem (NASDAQ:VSTM) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability.

Verastem presently has a consensus target price of $29.71, indicating a potential upside of 128.22%. Esperion Therapeutics has a consensus target price of $10.00, indicating a potential upside of 292.16%. Given Verastem's higher possible upside, analysts plainly believe Esperion Therapeutics is more favorable than Verastem.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Verastem
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00
Esperion Therapeutics
0 Sell rating(s)
4 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.43

Verastem has higher earnings, but lower revenue than Esperion Therapeutics. Verastem is trading at a lower price-to-earnings ratio than Esperion Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Verastem$2.60M126.69-$73.81M-$4.04-3.22
Esperion Therapeutics$116.33M2.49-$233.66M-$2.12-1.20

Esperion Therapeutics received 2 more outperform votes than Verastem when rated by MarketBeat users. Likewise, 69.64% of users gave Esperion Therapeutics an outperform vote while only 65.20% of users gave Verastem an outperform vote.

CompanyUnderperformOutperform
VerastemOutperform Votes
592
65.20%
Underperform Votes
316
34.80%
Esperion TherapeuticsOutperform Votes
594
69.64%
Underperform Votes
259
30.36%

Verastem has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500. Comparatively, Esperion Therapeutics has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500.

75.3% of Verastem shares are held by institutional investors. Comparatively, 69.8% of Esperion Therapeutics shares are held by institutional investors. 2.9% of Verastem shares are held by insiders. Comparatively, 0.6% of Esperion Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Esperion Therapeutics had 37 more articles in the media than Verastem. MarketBeat recorded 41 mentions for Esperion Therapeutics and 4 mentions for Verastem. Verastem's average media sentiment score of 0.86 beat Esperion Therapeutics' score of 0.37 indicating that Esperion Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Verastem
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Esperion Therapeutics
7 Very Positive mention(s)
4 Positive mention(s)
10 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Verastem has a net margin of 0.00% compared to Verastem's net margin of -179.87%. Verastem's return on equity of 0.00% beat Esperion Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
VerastemN/A -115.85% -52.62%
Esperion Therapeutics -179.87%N/A -91.62%

Summary

Esperion Therapeutics beats Verastem on 10 of the 18 factors compared between the two stocks.


Get Esperion Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ESPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ESPR vs. The Competition

MetricEsperion TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$289.99M$7.21B$5.20B$7.62B
Dividend YieldN/A2.84%2.82%3.87%
P/E Ratio-1.2011.78204.1516.27
Price / Sales2.49245.363,035.5480.31
Price / CashN/A19.0399.4255.35
Price / Book-0.644.694.534.54
Net Income-$233.66M$159.50M$114.95M$211.55M
7 Day Performance-2.30%7.84%5.70%3.36%
1 Month Performance16.44%15.85%11.24%6.68%
1 Year Performance-59.91%9.51%14.08%8.85%

Esperion Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VSTM
Verastem
2.3336 of 5 stars
$13.12
+0.2%
$29.71
+126.5%
+119.2%$331.94M$2.60M-3.2557Short Interest ↑
News Coverage
Gap Up
ATAI
Atai Life Sciences
2.254 of 5 stars
$2.00
+5.3%
$14.67
+633.3%
+32.3%$332.02M$230,000.00-4.44133
AKBA
Akebia Therapeutics
4.0322 of 5 stars
$1.64
+8.6%
$4.50
+174.4%
+86.9%$326.16M$292.60M-5.13204Short Interest ↓
News Coverage
QURE
uniQure
3.1502 of 5 stars
$6.75
+5.8%
$39.17
+480.2%
-74.0%$322.72M$106.48M-1.41501Analyst Downgrade
Insider Selling
Analyst Revision
News Coverage
Positive News
HOWL
Werewolf Therapeutics
2.7076 of 5 stars
$7.91
+7.6%
$10.58
+33.7%
+130.3%$321.62M$16.40M-7.1946Short Interest ↑
ACIU
AC Immune
1.9371 of 5 stars
$3.79
+0.5%
$16.00
+322.2%
+61.1%$320.07M$4.12M-4.26126Short Interest ↑
Gap Up
ME
23andMe
1.8999 of 5 stars
$0.66
+3.1%
$1.75
+164.1%
-76.6%$319.98M$299.49M-0.60769Gap Down
SBTX
Silverback Therapeutics
0 of 5 stars
$8.82
+0.8%
N/A-6.2%$318.03MN/A-3.6483High Trading Volume
NATR
Nature's Sunshine Products
2.6249 of 5 stars
$17.96
-1.9%
$21.50
+19.7%
+74.2%$342.68M$421.91M43.81800Positive News
NBTX
Nanobiotix
2.1003 of 5 stars
$6.54
+0.6%
$11.00
+68.1%
+83.2%$308.35M$5.12M0.00101Positive News

Related Companies and Tools

This page (NASDAQ:ESPR) was last updated on 3/2/2024 by MarketBeat.com Staff